Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis - Walsh, Michael; Merkel, Peter A; Peh, Chen-Au; Szpirt, Wladimir M; Puéchal, Xavier; Fujimoto, Shouichi; Hawley, Carmel M; Khalidi, Nader; Floßmann, Oliver; Wald, Ron; Girard, Louis P; Levin, Adeera; et al. (The New England journal of medicine, 2020)
Keywords: Administration, Oral; Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - mortality; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy; Antineutrophil cytoplasmic antibodies; Apheresis; Clinical trials; Combined Modality Therapy; Cyclophosphamide; Cyclophosphamide - therapeutic use; Death; Dose-Response Relationship, Drug; End-stage renal disease; Female; Glomerular filtration rate; Glucocorticoids; Glucocorticoids - administration & dosage; Glucocorticoids - adverse effects; Hemorrhage; Human health and pathology; Humans; Immunosuppressive Agents; Immunosuppressive Agents - therapeutic use; Incidence; Induction Chemotherapy; Kidney Diseases; Kidney Diseases - complications; Kidney Failure, Chronic; Kidney Failure, Chronic - epidemiology; Kidney Failure, Chronic - etiology; Kidney Failure, Chronic - prevention & control; Life Sciences; Male; Middle Aged; Patients; Plasma; Plasma Exchange; Plasma Exchange - adverse effects; Quality of life; Rituximab; Rituximab - therapeutic use; Statistical analysis; Urology and Nephrology; Vasculitis; Australia